 |
Atovaquone |
|---|---|
| Trade Name | Mepron |
| Orphan Indication | Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis |
| USA Market Approval | USA |
| USA Designation Date | 1993-03-16 00:00:00 |
| Sponsor | GlaxoSmithKline, Inc.;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709 |
